| 505 |
2 |
0 |
|g 1.
|t Cytokine Synergy in Immunotherapy /
|r J. W. Hadden, P. Malec, A. Saha and E. M. Hadden --
|g 2.
|t Monitoring Combination Therapy Trials: New Challenges for the Clinical Laboratory /
|r J. L. Rossio, H. C. Rager, C. S. Goundry and W. J. Urba --
|g 3.
|t IL-2-Based Consolidative Immunotherapy After Autologous Bone Marrow Transplantation /
|r A. Fefer, M. C. Benyunes, C. Higuchi, A. York, C. Massumoto, C. G. Lindgren, C. D. Buckner and J. A. Thompson --
|g 4.
|t Tumor Immunogenicity Induced by the Local Occurrence of IL-2 /
|r F. Cavallo, F. Di Pierro, M. Giovarelli, A. Vacca, A. Gulino, A. Soppacciaro, A. Modesti and G. Forni --
|g 5.
|t Thymosin [alpha][subscript 1]: Chemistry, Mechanism of Action and Clinical Applications /
|r A. L. Goldstein --
|g 6.
|t Combination Therapy with Thymosin [alpha][subscript 1] and Cytokines in the Treatment of Cancer and Infectious Diseases /
|r E. Garaci, A. Mastino, F. Pica and C. Favalli --
|g 7.
|t Effect of Thymosin [alpha][subscript 1] on Cocaine-induced Inhibition of T-Cell Dependent Murine Immune Response /
|r G. Ravagnan, R. Falchetti, P. Di Francesco, R. Gaziano, G. Lanzilli, C. Favalli and E. Garaci --
|g 8.
|t Regulation of Gene Expression by Interferons /
|r S. Landolfo, M. Gariglio, M. Gaboli, D. Lembo, A. Caliendo and R. Cavallo --
|g 9.
|t Interactions Between Tumor Necrosis Factor Alpha and Glucocorticoid Hormones in the Regulation of Tumor Cell Growth In Vitro /
|r I. Nicoletti, G. Migliorati, M. C. Pagliacci, F. Grignani and C. Riccardi --
|g 10.
|t Behavioural, Pyrogenic and Electrocortical Effects of Tumor Necrosis Factor-Alpha Given Intracerebrally in Rats /
|r G. B. De Sarro, D. Rotiroti and G. Nistico --
|g 11.
|t Biological Significance and Therapeutic Potential of Tumor-Associated Leukocytes /
|r A. Mantovani, B. Bottazzi, S. Sozzani, G. Peri, P. Allavena, A. Vecchi and F. Colotta --
|g 12.
|t Septic Shock Pathophysiology: Focus on Therapeutic Approach /
|r G. Palmieri, G. Nicoletti, S. Cantoni and L. Bucci --
|g 13.
|t Differentiating Agents and Cancer Therapy. Role of Cellular Lipid Peroxidation and its Product 4-Hydroxynonenal in the Control of Cell Proliferation and Differentiation /
|r V. M. Fazio, G. Barrera, R. Muraca, M. Rinaldi, S. A. Ciafre, M. Lazzari, M. U. Dianzani and M. Giulia Farace --
|g 14.
|t Inhibition of HIV Replication and Enhancement of Immune Functions by the Acyclic Nucleoside Phosphonate 9-(2-Phosphonyl-Methoxyethyl) Adenine (PMEA) /
|r C. F. Perno, V. Del Gobbo, J. Balzarini, E. Balestra, G. Milanese, A. Holy, E. De Clercq, N. Villani and R. Calio --
|g 15.
|t Modulation of Inflammatory Cytokines by a Receptor Antagonist, Autoantibodies, and Fever /
|r K. Bendtzen, M. B. Hansen and M. Svenson --
|g 16.
|t Cancer Immunochemotherapy: Preliminary Studies with Triazene Compounds /
|r G. Graziani, S. D'Atri, A. Giuliani, A. Franchi, D. Piccioni, G. Papa and E. Bonmassar --
|g 17.
|t Thymosin [alpha][subscript 1] and [alpha]-Interferon with Cisplatin and Etoposide in Advanced Non-Small Cell Lung Cancer: A Phase II Study /
|r M. Lopez, G. Bonsignore, M. D'Aprile, C. Favalli, M. Della Giulia, L. Di Lauro, P. Vici and E. Garaci --
|g 18.
|t Combination of Chronic Indomethacin and Intermittent IL-2 Therapy in the Treatment of Disseminated Cancer /
|r P. K. Lala, N. Al-Mutter, R. Parhar, M. N. Saarloos, D. Banerjee, V. Bramwell and W. C. Mertens --
|g 19.
|t Combination Chemotherapy and Cytokines in the Treatment of Advanced Primary Lung Cancer: Results of a Controlled Clinical Trial /
|r G. S. Del Giacco, G. Mantovani, P. Lai, E. Turnu, F. Locci, A. C. Scanu and G. Pusceddu --
|g 20.
|t Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes /
|r A. Venditti, M. T. Scimo, G. Del Poeta, R. Stasi, U. Coppetelli, M. Masi, M. Cecconi, M. Tribalto, G. Papa, C. Favalli and E. Garaci --
|g 21.
|t Myeloid Growth Factors in Cancer Treatment /
|r A. Butturini and R. P. Gale --
|g 22.
|t Efficacy of the Combined Treatment with Fluconazole and Thymosin [alpha][subscript 1] Against Candida albicans Infection in Morphine-Treated Mice /
|r P. Di Francesco, R. Gaziano, F. Pica, I. Casalinuovo, A. T. Palamara, L. Belogi, C. Favalli and E. Garaci --
|g 23.
|t Anti-Cytokine Therapy of Murine Candidiasis /
|r L. Romani, E. Cenci, A. Mencacci, R. Spaccapelo, E. Schiaffella, L. Tonnetti, P. Puccetti and F. Bistoni --
|g 24.
|t The Basic Research and Clinical Application of Thymopeptidin /
|r C. X. Zheng, C. S. Xu and S. Liu --
|g 25.
|t Treatment of Hepatitis C Virus-Associated Chronic Liver Disease with [beta]-Interferon and Inosine Pranobex: Combination Schedule vs. Monotherapies /
|r D. Sansonno, C. Azzolini and F. Dammacco --
|g 26.
|t Sustained Response to Thymosin Therapy in Patients with Chronic Active Hepatitis B /
|r M. G. Mutchnick, J. I. Jaurequi and D. A. Shafritz --
|g 27.
|t Combination Anti-HIV Therapy: Questions and Answers /
|r T. C. Merigan --
|g 28.
|t Mechanisms of Disease Progression and CD4 Depletion in HIV-1 Infection /
|r F. Aiuti, E. Scala, I. Mezzaroma, G. P. D'Offizi, R. Ferrara, G. Ricci and F. Pandolfi --
|g 29.
|t Combined Therapy with Zidovudine, Thymosin [alpha][subscript 1] and [alpha]-Interferon in the Treatment of HIV-Infected Patients /
|r E. Garaci, G. Rocchi, L. Perroni, C. D'Agostini, F. Soscia, A. Mastino, S. Grelli, C. F. Perno and C. Favalli --
|g 30.
|t The Problem of Interferon Species Appearing in Patients with Autoimmune Diseases /
|r L. Borecky, V. Lackovic, P. Kontsek, N. Fuchsberger, M. Kubes and J. Rovensky.
|
